The most closely watched drug program in Novartis' pipeline failed its most important test on September 8, when the company announced that del-desiran did not meet the primary endpoint of its Phase III HARBOR study in myotonic dystrophy type 1.
The result matters far beyond a single trial. Del-desiran was the centerpiece of Novartis' roughly $12 billion acquisition of Avidity Biosciences, a bet that the smaller company's muscle-targeting RNA technology could produce a first approved treatment for DM1, a progressive genetic disease that gradually weakens muscles and has no approved therapy anywhere in the world. Analysts had modeled peak sales as high as $6 billion for the drug, as Fierce Biotech reported. The miss does not kill the program, but it removes the straightest path to those projections.
What the trial measured, and what it found
HARBOR was a randomized, double-blind, placebo-controlled study of roughly 150 to 159 adults and adolescents with DM1. Participants received del-desiran or placebo every eight weeks for 54 weeks. The primary endpoint was video hand opening time, a measure of myotonia, the muscle-stiffening and delayed relaxation that is one of the disease's most disabling features. Patients open and close their hands on camera, and the test quantifies how long the muscles take to release.
Del-desiran did not separate from placebo on that measure with statistical significance. Novartis said signals of clinical activity appeared across secondary endpoints and exploratory analyses, including hand grip strength, quantitative muscle testing, activities of daily living, and a 10-meter walk/run test, but the company disclosed no numerical data, and secondary signals cannot rescue a failed primary endpoint. Safety findings were consistent with previously reported data.
The company said it will evaluate the complete dataset and engage with health authorities to determine the most appropriate development path. Shreeram Aradhye, Novartis' president of development, noted that DM1 still has no approved treatments and framed the setback as part of scientific progress.
Why the drug was supposed to work
Del-desiran is an antibody oligonucleotide conjugate, a newer drug class that attaches a small interfering RNA to an antibody. The antibody binds a receptor on muscle cells and delivers the RNA inside, where it degrades the toxic messenger RNA produced by the DMPK gene, the genetic error that causes DM1. The mechanism is designed to treat the disease's cause rather than its symptoms, which is why it carried FDA Orphan Drug, Fast Track, and Breakthrough Therapy designations into Phase III.
The early data supported the design. In the Phase I/II MARINA study, del-desiran produced roughly 40 percent mean reduction in DMPK mRNA and functional improvements across several measures. That evidence persuaded Novartis to pay the Avidity premium, and it persuaded regulators to allow the pivotal trial to move forward. The HARBOR result leaves an uncomfortable gap between the biology and the endpoint: the drug appears to do what it was built to do at the molecular level, and it did not do enough of what patients need at the clinical level.
For the roughly 40,000 to 80,000 people living with DM1 in the United States and Europe, the outcome is a familiar one in rare disease: a promising program that will now take longer, or possibly never arrive. The disease's progression, from muscle stiffness and weakness to effects on the heart, breathing, and cognition, has no approved therapy to slow it, and the standard of care remains symptom management.
What survives the miss
The HARBOR failure does not touch Novartis' other programs from the Avidity deal. Del-zota, the company's Duchenne muscular dystrophy candidate, has FDA Priority Review, and del-brax for facioscapulohumeral muscular dystrophy continues to advance. The antibody-oligonucleotide platform itself is not discredited; one trial can fail for reasons specific to its disease, its endpoint, or its duration, and the Duchenne and FSHD programs will now carry the platform's credibility forward.
Still, the setback rearranges Novartis' rare-disease narrative. The acquisition's returns were always going to be judged against DM1, the indication with the largest unmet need and the clearest regulatory path. The company's statements keep every option open, from a new pivotal trial with a different endpoint to a narrower approval path based on the secondary signals. What the statements cannot do is restore the timeline the miss erased.
For patients and families watching, the honest summary is simple: the drug's most direct route to approval is closed, and the work of finding another route has just begun.
Primary sources
- Novartis media release on the HARBOR study results.
- Fierce Biotech for the Avidity acquisition context and analyst expectations.
- NeurologyLive for the trial design and the vHOT primary endpoint.